ePrints

Outcomes from the International Society of Nephrology Hemolytic Uremic Syndromes International Forum

Lookup NU author(s): Professor David KavanaghORCiD, Dr Vicky Brocklebank, Dr Sally Johnson, Professor Neil SheerinORCiD

Downloads

• Published version [.pdf]

Licence

This work is licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0).

Abstract

The haemolytic uraemic syndromes (HUS) are a heterogeneous group of conditions only some of which are mediated by complement. We report the outcome of the 2023 International Society of Nephrology HUS International Forum where a global panel of experts considered the current state of the art, identified areas of uncertainty, and proposed optimal solutions. Areas of uncertainty and areas for future research included: the nomenclature of HUS; novel complement testing strategies; identification of biomarkers; genetic predisposition to aHUS; optimal dosing and withdrawal strategies for C5 inhibitors; treatment of kidney transplantation recipients; disparity of access to treatment; and the next generation of complement inhibitors in aHUS. The current rationale for optimal patient management is described.

Publication metadata

Author(s): Kavanagh D, Ardissino G, Brocklebank V, Bouwmeester R, Bagga A, terHeine R, Johnson S, Licht C, Ma A, Noris M, Praga M, Rondeau E, Sinha A, Smith RJH, Sheerin NS, Trimarchi H, Wetzels J, Vivarelli M, Van de Kar N, Greenbaum LA

Publication type: Article

Publication status: Published

Journal: Kidney International

Year: 2024

Volume: 106

Issue: 6

Pages: 1038-1050

Print publication date: 01/12/2024

Online publication date: 10/10/2024

Acceptance date: 04/09/2024

Date deposited: 06/09/2024

ISSN (print): 0085-2538

ISSN (electronic): 1523-1755

Publisher: Elsevier Inc.

URL: https://doi.org/10.1016/j.kint.2024.09.012

DOI: 10.1016/j.kint.2024.09.012

PubMed id: 39395628

Notes:

Altmetrics

Share